EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures

Nobuyuki Ono iD, Motoki Yoshimura, Toshiya Nishida, Yusuke Yamauchi, Goro Doi, Yoko Fuyuno, Motoshi Sonoda, Hiroaki Niiro iD

Modern Rheumatology Case Reports · 2025

DOI: 10.1093/mrcr/rxaf016 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Nobuyuki Ono und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Biosystem Science, Graduate School of Medical Science, Faculty of Medicine, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Macrophage Activation Syndrome, Pyrin. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophage activation syndrome (MAS) is an autoinflammatory condition, which severely complicates autoimmune diseases, such as systemic juvenile idiopathic arthritis, adult onset Still’s disease, and systemic lupus erythematosus. MEFV gene encodes a component of pyrin inflammasome, whose variants cause familial Mediterranean fever (FMF). We experienced a recurrent MAS case with homozygous MEFV P369S variants accompanied by Sjögren syndrome and pulmonary arterial hypertension, whose recurrent MAS was successfully treated with canakinumab. Pathogenicity of MEFV P369S variant is still inconsistent, and clinical interpretation of this variant is challenging. Thus, we reviewed previous literatures and revealed that the majority of FMF patients with collagen diseases in carried MEFV P369S variant, all of which were reported from Japan. In this case-based review, we clarify the epidemiology of MEFV variants in collagen diseases and discuss the significance of their genetic analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedMacrophage Activation SyndromePyrinSjogren's SyndromeFemaleHumansHomozygoteRecurrenceTreatment Outcome

Stichwörter der Autor:innen

MEFVMacrophage activation syndromeSjögren syndromecanakinumabfamilial Mediterranian fever

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedcanakinumabMEFV protein, humanPyrin

Autor:innen und Institutionen

  • Department of Medicine and Biosystem Science, Graduate School of Medical Science, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
  • Department of Rheumatology, Fukuoka City Hospital, Fukuoka, Japan.
  • Department of Clinical Immunology and Rheumatology/Infectious Disease, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Rheumatology, Iizuka Hospital Iizuka Hospital, Fukuoka, Japan.
  • Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan.
  • Department of Dermatology, Kyushu University Hospital, Fukuoka, Japan.

ORCID-Profile: Nobuyuki Ono, Hiroaki Niiro

Zitieren

APA

Ono, N., Yoshimura, M., Nishida, T., Yamauchi, Y., Doi, G., Fuyuno, Y., Sonoda, M., & Niiro, H. (2025). Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxaf016

Vancouver

Ono N, Yoshimura M, Nishida T, Yamauchi Y, Doi G, Fuyuno Y, et al. Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxaf016

BibTeX
@article{Ono2025,
  author = {Ono, Nobuyuki and Yoshimura, Motoki and Nishida, Toshiya and Yamauchi, Yusuke and Doi, Goro and Fuyuno, Yoko and Sonoda, Motoshi and Niiro, Hiroaki},
  title = {Successful control of recurrent MAS by canakinumab in a Sjögren syndrome patient with homozygous MEFV P369S variants and review of literatures},
  journal = {Modern Rheumatology Case Reports},
  year = {2025},
  doi = {10.1093/mrcr/rxaf016}
}
Kostenlos starten →